Neurocrine Gets Rights to GBA1 Gene Therapy Work for Parkinson’s
Neurocrine Biosciences has acquired rights to Voyager Therapeutics’ experimental gene therapy program for Parkinson’s disease…
Articles by Lindsey Shapiro, PhD
Duopa Found to Quickly Ease Motor Fluctuations in Phase 3 Trial
One year of treatment with Duopa, a levodopa/carbidopa intestinal gel, led to fast and sustained reductions in motor fluctuations…
Mediterranean Diets Linked to Reduced Symptom Burden
Better adherence to Mediterranean-style diets is associated with lower patient-reported symptom severity in people with Parkinson’s disease, according…
Golexanolone Eases Cognitive, Motor Symptoms in Parkinson’s Rat Model
Golexanolone, an investigational small molecule from Umecrine Cognition, reversed cognitive and motor symptoms in a rat model of…
Top 10 Parkinson’s Disease Stories of 2022
Throughout 2022, Parkinson’s News Today brought you daily coverage of the latest scientific breakthroughs and treatment advancements related to…
CST-103 Shows Potential to Safely Aid Cognition in Phase 2 Trial
Treatment with CST-103, CuraSen Therapeutics’ investigational oral molecule, safely led to cognitive improvements in people with Parkinson’s…
RNA Pathway May Help Advance Early Diagnosis and Treatment
A family of proteins called Piwis and the tiny regulatory RNA molecules they interact with — Piwi-interacting RNA (piRNA) —…
Gene Therapy SLS-004 Prevents Neurodegeneration In Mouse Model
SLS-004, Seelos Therapeutics‘ investigational gene therapy for Parkinson’s disease, lowered alpha-synuclein levels and prevented the degeneration of dopamine-producing,…
AL101 Safely Increases Progranulin Levels in Phase 1 Trial
Multiple doses of AL101, Alector’s investigational treatment for neurodegenerative diseases such as Parkinson’s, safely increased progranulin levels in…
Dry Eye Disease Appears to Affect Many Parkinson’s Patients
Dry eye disease (DED) is common in people with Parkinson’s disease, with more than 60% of patients reporting that…